Harvard Business School Kraft Precision Medicine Accelerator Brings Together Five Leading Cancer Organizations to Engage Patients and Accelerate Precision Medicine across Cancers

[LaurenH]

The Harvard Business School Kraft Precision Medicine Accelerator, a multidisciplinary initiative that uses collective impact to advance high-priority opportunities in precision medicine, announced today that five leading cancer organizations have come together to share best practices, engage patients, and create synergies to advance precision medicine opportunities across cancers. The organizations include LUNGevity Foundation, the Metastatic Breast Cancer Alliance, the Multiple Myeloma Research Foundation (MMRF), the Pancreatic Cancer Action Network (PanCAN), and the Prostate Cancer Foundation.

The Accelerator has begun testing the “Right Track”, a framework to help patients optimize their treatment journey by connecting them with patient-focused organizations. Cancer patients are often overloaded with information and don’t know what steps to take with their treatment. Market research supported by the Accelerator identified consistent gaps in knowledge and actions among patients with five types of cancer. The Accelerator developed the Right Track using this market research and will be testing the program with the goal of closing these knowledge gaps.

The Kraft Precision Medicine Accelerator brings together diverse, best-in-class leaders and health care stakeholders to develop a business framework to drive and disseminate solutions to advance precision medicine. The Accelerator focuses on four workstreams -- Direct to Patient, Data & Analytics, Clinical Trials, and Venture and Investment – all critical elements of precision medicine.

The Direct to Patient workstream is supported by marketing innovators from leading consumer companies such as Marriott International, Rent the Runway, Keurig Green Mountain, Reebok, Rue La La, and leading tech companies, to help the five cancer organizations create the kind of direct relationships with patients that precision medicine needs to foster.

“The Accelerator uses ‘collective impact’ – a framework based on the idea that tackling complex, systematic issues like cancer can only be achieved when diverse stakeholders work toward a shared goal,” said Lori Marcus, Chair of the Accelerator’s Direct to Patient workstream. “By bringing together leading cancer organizations and some of the world’s top consumer companies that have built loyal customer followings, we can help close knowledge gaps and increase patient engagement across cancers.”

Read the full press release.